Comparison · NCT05505734-sae
BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events. Trial comparisons, record NCT05505734-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05505734-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0306 | 0.0223 | 0.0419 | wilson | |
| Risk in group 2 | 0.0305 | 0.0222 | 0.0418 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0000758 | -0.0139 | 0.0141 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.64 | 1.57 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.631 | 1.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on BDA MDI (PT027) 160/180 μg than on AS MDI (PT007) 180 µg | 13,200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BDA MDI (PT027) 160/180 μg | Budesonide/albuterol sulfate, BDA MDI, PT027~Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg: Budesonide/albuterol sulfate combination inhalation aerosol | 37 | 1,209 | EG000 |
| Group 2 | AS MDI (PT007) 180 µg | Albuterol sulfate MDI, PT007~Albuterol sulfate metered-dose inhaler 180 μg: Albuterol sulfate inhalation aerosol | 37 | 1,212 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality (death due to any cause): from randomization up to and including the final DCO (20 September 2024) or study discontinuation, up to 1 year. Treatment-emergent adverse events: from treatment initiation until the earliest occurrence of study completion or treatment discontinuation, up to 1 year.
Source ClinicalTrials.gov
Trial
- Title
- A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
- NCT number
- NCT05505734
- Phases
- PHASE3
- Conditions
- Asthma
- Interventions
- BDA MDI, AS MDI
- Lead sponsor
- Bond Avillion 2 Development LP
- Results first posted
- 2025-08-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05505734?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05505734-sae